Zacks Investment Research upgraded shares of Radius Health (NASDAQ:RDUS) from a hold rating to a buy rating in a research note published on Thursday. They currently have $18.00 price target on the biopharmaceutical company’s stock.
According to Zacks, “Radius got a boost with the approval of lead drug Tymlos. Sales of Tymlos continue to gain traction. Total prescriptions accounted for 22% of total U.S. anabolic osteoporosis market (based on Patient Months on Therapy, TRx PMOT) in the quarter. Tymlos is expected to be covered for approximately 274 million insured lives, representing approximately 95% of U.S. commercial and 64% of Medicare insured lives effective Jan 1, 2019. However, Radius suffered a setback when the CHMP communicated a negative trend vote for the MAA following a re-examination procedure of lead drug Tymlos. Thereafter, the CHMP communicated that it maintained its negative opinion on the MAA at its formal final vote. While the market for postmenopausal osteoporosis provides significant commercial potential, it is pretty crowded given the presence of products like Amgen’s Prolia and Lilly’s Forteo. Shares have underperformed the industry so far.”
Several other brokerages have also commented on RDUS. Jefferies Financial Group reiterated a hold rating and issued a $25.00 target price on shares of Radius Health in a research report on Tuesday, August 7th. Cowen reiterated a hold rating on shares of Radius Health in a research report on Thursday, October 18th. BidaskClub upgraded Radius Health from a strong sell rating to a sell rating in a research report on Tuesday, October 2nd. Finally, JPMorgan Chase & Co. decreased their target price on Radius Health from $59.00 to $52.00 and set an overweight rating for the company in a research report on Friday, November 2nd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. Radius Health currently has a consensus rating of Hold and an average target price of $44.38.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.17. Radius Health had a negative return on equity of 140.79% and a negative net margin of 346.67%. The company had revenue of $27.70 million for the quarter, compared to the consensus estimate of $26.00 million. During the same period in the previous year, the business earned ($1.31) EPS. Radius Health’s revenue for the quarter was up 105.2% compared to the same quarter last year. Sell-side analysts expect that Radius Health will post -5.17 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the stock. NumerixS Investment Technologies Inc acquired a new position in Radius Health during the 2nd quarter valued at approximately $162,000. Belpointe Asset Management LLC acquired a new position in Radius Health during the 3rd quarter valued at approximately $110,000. Cubist Systematic Strategies LLC boosted its position in Radius Health by 9,303.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 9,403 shares of the biopharmaceutical company’s stock valued at $277,000 after purchasing an additional 9,303 shares during the period. Pacer Advisors Inc. acquired a new position in Radius Health during the 3rd quarter valued at approximately $186,000. Finally, Verition Fund Management LLC acquired a new position in Radius Health during the 3rd quarter valued at approximately $208,000.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
Read More: Understanding Analyst Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.